Jyong Biotech Ltd. (Nasdaq stock code: MENS) (hereinafter referred to as “the Company” or “Jyong Biotech”) is a science-driven biotechnology company dedicated to developing and commercializing innovative plant-based therapies. The Company recently announced that, following an analysis of the clinical efficacy and competitive advantages of its innovative botanical drugs Botreso® and PCP, it has advanced its market access strategy.

As previously announced by the company, its first core product, Botreso®, has completed four Phase III clinical trials (API-1) in the United States and Taiwan, while its second core product, PCP, has successfully completed a Phase II clinical trial. Overall clinical data demonstrate that Jyong Biotech’s innovative botanical drugs exhibit significant differentiation advantages compared to currently marketed synthetic chemical drugs.

Overall Safety Profile for Long-Term Use

For middle-aged and elderly males requiring long-term medication, safety is one of the most decisive factors. In clinical trials—Botreso® (Phase III) had a treatment duration of one year, while PCP (Phase II) lasted two years—no drug-related serious adverse events were observed, demonstrating excellent safety and tolerability.

In contrast, currently available chemically synthesized drugs for the treatment of benign prostatic hyperplasia (BPH) are often associated with adverse effects such as postural hypotension, erectile dysfunction, and decreased libido. Regulatory authorities and research institutions have linked certain synthetic alternative medications to significant risks, prompting the U.S. Food and Drug Administration (FDA) to issue a safety advisory regarding advanced prostate cancer and depression in 2011, and to include suicidal ideation in its list of adverse reactions in 2022. Additionally, an independent study conducted in 2021 also established associations between these drugs and cardiac failure.

Management of risks associated with advanced prostate cancer

Large-scale international clinical trials have demonstrated that while certain synthetic drugs used to treat benign prostatic hyperplasia (BPH) can reduce the overall incidence of prostate cancer, they may paradoxically increase the proportion of advanced prostate cancer (Grisson score ≥ 7) when cancer develops, thereby posing significant clinical safety concerns.

The Phase II clinical trial of PCP was a large-scale, long-term study on rare conditions conducted in Taiwan across 20 major hospitals. Over a period of two years, the trial involved 135 urologists (representing more than one-tenth of all urologists in Taiwan) and enrolled a total of 702 participants. It was one of the first global clinical trials specifically targeting prostate cancer prevention using a novel botanical drug conducted in Taiwan. The results demonstrated that PCP exhibited a downward trend in both overall prostate cancer incidence and the risk of advanced-stage prostate cancer, effectively addressing concerns within the medical community regarding the risks associated with existing therapies.

Comprehensive approach of “Treatment + Prevention + Metabolic Management”

Based on the clinical data from the company’s conducted trials, the company believes it is establishing a differentiated product positioning.

• Improvement of lower urinary tract symptoms (LUTS): Effectively alleviates symptoms associated with benign prostatic hyperplasia.

• Prevention of prostate cancer: Demonstrates prophylactic clinical potential.

• Metabolic and cardiovascular protection: Decreased triglyceride levels (P=0.05), significantly reduced total cholesterol and low-density lipoprotein (bad cholesterol) (P<0.05), significantly increased high-density lipoprotein (good cholesterol) (P<0.05), and maintained stable blood glucose levels.

This comprehensive therapy delivers benefits without adversely affecting blood pressure, liver function, or renal function. The company emphasizes that this integrated approach combining treatment, prevention, and metabolic management is exceptionally rare among current prostate medications and holds significant appeal for men aged 40 and above.

Technical Barriers and Competitive Advantages

Due to the inherent complexity and diversity of components in novel botanical drugs, quality control poses greater challenges compared to that of small-molecule chemical drugs. Jianyong Biotechnology asserts that the company has successfully established a comprehensive technical platform, which includes:

• Purification and establishment of reference standards.

• Development and validation of analytical methods.

• Perform the validation analysis and verification process.

The company believes that such comprehensive capabilities create substantial market entry barriers, rendering the products highly difficult to replicate. Furthermore, they effectively mitigate risks associated with competition from counterfeit and substandard products as well as generic drugs, ultimately contributing to an extended period of market monopoly.

The upgraded market positioning and strategic value

As a plant-based new drug protected by global patents, Jyong Biotech believes its market strategy leverages the following key advantages:

• Pricing competitiveness: Its unique metabolic protection profile and safety profile enable it to command higher prices compared to non-patented generic drugs, making it attractive to both out-of-pocket and high-end healthcare markets.

• Authorization potential: The combination of high tolerability, excellent safety profile (no serious adverse reactions), and multiple clinical benefits makes it an ideal target for international pharmaceutical collaboration.

• Market scalability: Expanding the product portfolio from treatment-oriented approaches to the fields of preventive medicine and health management.

Globally, over 500 million men aged 50 and above seek treatment for benign prostatic hyperplasia (BPH). In 2020, the global BPH drug market was valued at $4.1 billion and is projected to reach $9.8 billion by 2026. Although the current treatment market generates annual revenues of approximately $6.5 to $7 billion, this figure reflects price reductions due to patent expiration. If calculated based on prices during the patent period, the market potential exceeds $20 billion annually.

“Due to the complex composition of botanical new drugs, they face significant challenges in quality control compared to small-molecule chemical drugs,” stated Chairman Guo of Jianyong Biotechnology. “We have established a robust technical platform that encompasses the purification of reference standards, development and validation of analytical methods, as well as performance validation analyses. This high entry barrier makes counterfeiting difficult to achieve, reduces competition from generic drugs, and helps extend market exclusivity periods.”

Chairman Guo stated: “Botreso® is Taiwan’s first oral botanical drug to obtain an IND approval from the U.S. FDA for Phase III clinical trials (API-1) and has successfully completed all four Phase III clinical trials.”

Jyong Biotech holds multiple invention patents across Asia, the Americas, and the European Union, and has signed letters of intent and investment agreements with several international pharmaceutical companies. The company plans to further expand its strategic, fee-based licensing partnerships to support its global market expansion.

As of today, Botreso® and PCP remain in the investigational new drug candidate stage and have not yet been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on significant progress.

Company Profile: Jyong Biotech Ltd., headquartered in Taiwan, is a science-driven biotechnology company dedicated to the research, development, and commercialization of innovative and differentiated novel drugs (of plant origin), with a primary focus on the treatment of urinary system disorders, initially targeting the markets in the United States, the European Union, and Asia. Since its establishment in 2002, the company has developed comprehensive capabilities encompassing all critical stages of drug development, including early-stage drug discovery and development, pharmacology, toxicology, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging robust R&D capabilities and proprietary platforms, the company has developed a portfolio of plant-derived candidate drugs, including its lead plant-based candidate Botreso®, another plant-based candidate drug in clinical development, and several other plant-based candidates in preclinical stages. The company is committed to developing and delivering cutting-edge innovative therapeutics to address customer health needs and strives to become a respected and valuable enterprise.

For more information, please contact:

Jyong Biotech Ltd.

ir@jyongbio.com

Investor Relations Department

WFS Investor Relations Inc.

Mailbox: services@wfsir.com

Phone: +1628 283 9214

United States, 16th Jul 2026, – As the global cycling industry gathers in Frankfurt from June 24 to 27, 2026, TARRAN will exhibit at Booth F12 B26, where the company will debut the new L1 Series alongside its flagship model, the T1 Pro. Visitors can experience both models firsthand at the booth.

Following last year’s market launch of the T1 Pro, Tarran is expanding its portfolio, combining engineering precision with the demands of everyday urban riding.

Featured Models

L1 Series: New for 2026

The new model is engineered for practical everyday use. As TARRAN’s first intelligent longtail cargo bike designed for families, its core innovations include the industry-first SyncStand Auto, an electronic kickstand that parks the bike at the push of a button, and an E-Dropper Post that adjusts saddle height instantly.

Paired with Enviolo AUTOMATIQ Pro automatic shifting, fully integrated into TarranOS, the L1 delivers an intuitive, low-effort riding experience. It features a 100 Nm mid-drive motor, a removable 693 Wh battery built with Samsung cells, and a reinforced longtail frame supporting a maximum gross vehicle weight of 215 kg (474 lb).

For rider and passenger safety, the Vision Unit—combining a rear-view camera and mmWave radar—works together with integrated front and rear turn signals to provide 360-degree protection for the whole family. TARRAN continuously improves the L1 through over-the-air updates, supporting long-term product maintenance and ongoing refinement. A firmware update scheduled for late June will add native control for DJI action cameras and an anti-pinch safety function for the electronic kickstand.

T1 Pro

Successfully launched last year, the flagship model continues to demonstrate the brand’s technological strengths. The T1 Pro is equipped with active safety systems that monitor the bike’s surroundings and assist the rider in critical situations.

The T1 Pro features Tarran’s proprietary Dynamic Dualdrive landing gear, which stabilizes the bike while riding and at a standstill, reducing the risk of tipping. It is designed to carry families with two to three children in comfort, while its compact 2.26-meter (7.4 ft) overall length ensures agile handling.

Putting the Riding Experience First

Tarran believes that genuine innovation is best understood through direct experience. While the exhibit offers a closer look at the underlying technical architecture, consumers and e-bike enthusiasts are welcome to test ride both models directly at the TARRAN booth.

Visitors can see for themselves how the intuitive controls and safety features change the riding experience in urban environments.

Global Growth and Dealer Network

Reflecting TARRAN’s continued growth, and with the L1 Series now in series production, the brand’s products are available in more than 100 retail stores worldwide.

Strengthening its global footprint, TARRAN is now formally entering the North American market, actively building a dealer network across the United States and Canada to bring its intelligent, safety-focused cargo bikes to more families.

Expert Dialogue and Consultations

Tarran offers trade journalists and partners the opportunity for individual, in-depth background briefings. On-site experts will be available in the following areas:

Product Development and Technology: Shiyuan, Product Manager.

Strategy and Marketing: Dennis Wang and Larry Hu.

DACH Region Sales: Sebastian Locher and Jiaming Lee.

Benelux Region Sales: Fabian Hard.

Press Contact and Scheduling: To arrange a briefing or a test ride, please contact tarran@laika.berlin.

About TARRAN

Founded in 2023, TARRAN develops human-centered mobility experiences that combine clean energy with intelligent systems, with the goal of accelerating the transition to a more sustainable future.

The team draws on experience from leading technology companies, including DJI, and believes that technology can help solve real-world challenges while making a positive contribution to the world we live in.

TARRAN currently operates across three locations: Dusseldorf, Hong Kong, and Shenzhen. Its research, development, and testing center is located in Shenzhen, while its manufacturing hubs are situated in Europe and Southeast Asia.

Media Contact

Organization: Tarran GmbH

Contact
Person: Media Relations

Website:

https://tarranbikes.com/

Email:

store@tarranbikes.com

Contact Number: 8618898353598

Country:United States

The post
Experience the Future of Urban Mobility Firsthand: Tarran Presents the New L1 Series at Eurobike 2026 appeared first on
Brand News 24.
It is provided by a third-party content
provider. Brand News 24 makes no
warranties or representations in connection with it.

Austin, Texas, July 16th, 2026, FinanceWire

The new report, titled “Back to Basics,” examines bitcoin’s fundamentals, the limits of paper exposure, and the data behind the current buying opportunity, paired with 50% off trading fees and no-cost recurring buys.

Onramp, the bitcoin-centric financial services platform built on Multi-Institution Custody, today released Back to Basics, a summer 2026 research report making the case for owning bitcoin directly at one of the most asymmetric moments in the asset’s history. Bitcoin currently trades roughly ~50% below its late-2025 high, the shallowest drawdown on record by bitcoin’s own historical standard, while the S&P 500 sits within ~1% of its all-time high, the Nasdaq within ~4%, and gold within ~24% of its peak. Alongside the report, Onramp is offering 50% off trading fees and no-cost recurring buys for new clients. The report and offers are available here. 

The timing reflects a deliberate view on where the current cycle stands. Prior drawdowns reached 93% in 2011, 85% from 2013 to 2015, 83% in 2017 to 2018, and 77% from 2021 to 2022. Each ended in a new all-time high. The current cycle’s ~50% decline is the shallowest in bitcoin’s history, occurring as the Fear & Greed Index sits at 22, in extreme-fear territory, at the time of writing. The report arrives at the moment sentiment is at its worst and the historical data makes the clearest case for accumulation.

Back to Basics is organized in three sections. The first covers ten foundational ideas behind owning bitcoin: why fiat currency is designed to lose value, how a capped supply of 21 million makes bitcoin’s scarcity verifiable rather than promised, and why direct ownership differs meaningfully from holding an instrument that tracks the price. The second examines the full range of bitcoin exposure, from ETF shares and exchange balances to structured products and treasury equities, laying out what holders actually own in each case and where the counterparty risk sits. The third presents the data: where the current drawdown sits relative to prior cycles and the pattern of recoveries that have followed comparable declines.

“We find that a meaningful share of people who consider themselves bitcoin owners actually hold a paper claim against it. You get the price exposure, but not the asset itself,” said Michael Tanguma, Founder and CEO of Onramp. “That’s what Back to Basics is designed to address. Whether you’ve never owned real bitcoin or you’ve been sitting in a wrapper for years, this campaign is the on-ramp to the real thing. There’s no substitute for holding it directly.” 

The report makes clear that paper exposure, however convenient, reintroduces the counterparty risk bitcoin was designed to eliminate. A balance at an exchange is the obligation of a platform that may have lent the coins elsewhere. A fund share is a claim on a fund that holds a claim with a custodian. A yield-bearing product passes a borrower’s risk to the holder as a return. A share in a bitcoin-holding company embeds the asset inside a business with its own leverage and dilution. With each step away from the underlying asset, the holder gains convenience and accepts an additional party between themselves and their bitcoin.

“The fundamentals have not changed. The price has,” said Brian Cubellis, Chief Strategy Officer at Onramp. “Back to Basics gives investors the data and the framework to recognize this for what it is, one of the most compelling accumulation windows in bitcoin’s history, and to act on it.”

The campaign also marks the launch of recurring buys on Onramp, a new feature available to every client with no fees that lets investors dollar-cost average into bitcoin automatically on a schedule they set. Alongside it, both new and existing clients get 50% off the fees on every bitcoin buy and sell through September 7, plus free access to the Back to Basics report.

For those looking to do more, the first 100 clients to open an Onramp Bitcoin IRA pay no first- -year-fees. Separately, clients can access Multi-Institution Custody, the 2-of-3 model Onramp pioneered, at a reduced rate of $100 per month.

Back to Basics also marks an expansion of Onramp Media, the company’s editorial arm. The same week the report was released, Onramp debuted Signal vs. Noise, a new weekly show in which four hosts each bring their top stories to the table and the strongest survive, a format built to separate what matters in markets from what merely trends. Alongside the show, Onramp is standing up a dedicated editorial news desk covering money, markets, and the forces reshaping both. The premise mirrors the report itself: strip away the noise, return to the fundamentals, and follow the signal.

The full report and all offers are available here. 

About Onramp

Onramp is a financial platform for people who think about wealth in decades. Onramp Finance, its latest offering, unifies cash accounts with Onramp-funded rewards up to 5% through a partnership with Bridge, a spending card with up to 1.5% cash back, low-cost bitcoin brokerage in all 50 states, bitcoin IRAs, and direct gold access in a single account. Onramp pioneered Multi-Institution Custody (MIC), a model that eliminates reliance on any single custodian by distributing security across independent institutions including Onramp, BitGo, Coincover, and Tetra. No single institution can access, move, or lose a client’s bitcoin. Bitcoin held in MIC is insured by Lloyd’s of London. Users can learn more at onrampbitcoin.com.

For media inquiries: phil@21mcommunications.com 

Contact

Founder
Phil
21M Communications
phil@21mcommunications.com